右美托咪定减轻肺癌胸腔镜术后炎症反应与慢性疼痛
这项随机对照试验纳入152例择期行电视辅助胸腔镜肺癌手术患者,随机分为右美托咪定组与生理盐水组各63例完成分析。右美托咪定在麻醉诱导前10分钟按0.6 μg/kg给药,并维持0.5 μg/kg/h至手术结束前0.5小时。结果显示其可降低促炎细胞因子与氧化应激标志物、升高白细胞介素-10与超氧化物歧化酶,并减轻术后疼痛、加快康复,未增加不良反应或并发症风险。
要点
- 右美托咪定降低白细胞介素-1β、白细胞介素-6、肿瘤坏死因子-α及活性氧、丙二醛水平。
- 右美托咪定组术后疼痛评分更低、镇痛泵按压次数更少、胸管拔除更快、住院时间更短。
- 该方案未增加不良反应或并发症风险,可安全用于肺癌胸腔镜手术围术期。
核心结论
- 右美托咪定可有效减轻肺癌胸腔镜手术后的炎症反应、氧化应激与术后疼痛,促进患者康复,且不增加不良反应或并发症风险。
研究设计与样本
- 随机对照试验,纳入152例择期行电视辅助胸腔镜手术的肺癌患者,右美托咪定组与生理盐水组各63例纳入分析。
- 右美托咪定于麻醉诱导前10分钟按0.6 μg/kg给药,并维持0.5 μg/kg/h至手术结束前0.5小时;两组麻醉与术后镇痛方案标准化。
主要发现
- 右美托咪定组白细胞介素-1β、白细胞介素-6、肿瘤坏死因子-α及活性氧、丙二醛水平降低,白细胞介素-10与超氧化物歧化酶水平升高。
- 右美托咪定组术后疼痛数字评分更低、麻醉药用量更少、胸管拔除更快、镇痛泵按压次数更少、术后住院时间更短。
关键数值与推荐
- 右美托咪定剂量为麻醉诱导前10分钟0.6 μg/kg,维持0.5 μg/kg/h至手术结束前0.5小时。
- 主要观察指标包括生命体征、疼痛数字评分、血液炎症与氧化应激标志物、疼痛类型与部位、镇痛泵使用、麻醉药与补救镇痛药用量及并发症。
临床怎么用
- 对择期肺癌胸腔镜手术患者,可考虑围术期按上述方案泵注右美托咪定以减轻炎症与疼痛、促进康复。
- 用药期间需按试验方案监测生命体征、疼痛评分及并发症,并配合标准化麻醉与术后镇痛流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of the present study was to evaluate the effect of dexmedetomidine administration during video-assisted thoracoscopic surgery for lung cancer on perioperative inflammatory response and chronic post-surgical pain. METHODS: A cohort of 152 patients with lung cancer scheduled for elective video-assisted thoracoscopic surgery participated in this randomized controlled trial. Patients were randomly divided into 2 groups and administered an equivalent volume of dexmedetomidine (n = 63) or normal saline (n = 63). Dexmedetomidine was administered at a dose of 0.6 μg/kg 10 minutes before anesthesia induction and maintained at 0.5 μg/kg/h until 0.5 hours before surgery completed. Anesthesia and postoperative pain management protocols were standardized for both groups. The analysis included vital signs, numerical rating scales of pain, blood inflammatory and oxidative stress biomarkers, pain type and location, patient-controlled intravenous analgesia usage, consumption of general anesthetics and pain rescue medications, as well as complications. RESULTS: The administration of dexmedetomidine resulted in decreased levels of inflammatory cytokines (interleukin-1 beta, interleukin-6, alongside tumor necrosis factor-alpha) and oxidative stress biomarkers (reactive oxygen species alongside malondialdehyde) but elevated levels of interleukin-10 and superoxide dismutase. In addition, the dexmedetomidine group showed lower postoperative numerical rating scale scores, reduced consumption of anesthetics, faster chest-tube removal, fewer patient-controlled intravenous analgesia presses, and shorter postoperative hospital stays. CONCLUSION: The administration of dexmedetomidine effectively attenuated surgical inflammation, oxidative stress, and postoperative pain, thereby promoting patient recovery after lung cancer surgery without increasing the risk of adverse effects or complications.
引用
- Zhong S, Sun Q, Wen J, et al. Dexmedetomidine attenuates inflammatory response and chronic pain following video-assisted thoracoscopic surgery for lung cancer. Surgery. 2024. PMID: 38997865. doi:10.1016/j.surg.2024.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。